Pfizer, facing declining share price and strategic criticism, is under pressure from activist investor Starboard Value, which has acquired a $1 billion stake in the company. Starboard is pushing for a more focused development strategy and deeper cost cuts, aiming to turn around the pharmaceutical giant’s fortunes.